17
DEC
2012

Northwest Biotherapeutics To Ring The NASDAQ Stock Market Opening Bell

Posted By :
Comments : Off
BETHESDA, MD, Monday, December 17, 2012 – Northwest Biotherapeutics, Inc. (NASDAQ: NWBO; NWBOW) (NW Bio), a biotechnology company developing DCVax® personalized immune therapies for cancer, announced today that it is scheduled to ring The NASDAQ Stock Market Opening Bell on Tuesday, December 18, 2012 to celebrate the Company’s recent financing and up-listing to the NASDAQ Capital Market. NW Bio’s common stock and warrants began trading on...
Read More
12
DEC
2012

Northwest Biotherapeutics, Inc. Announces Full Exercise of OverAllotment Option

Posted By :
Comments : Off
BETHESDA, MD., December 12, 2012 – Northwest Biotherapeutics, Inc. (Nasdaq: NWBO; NWBOW), a biotechnology company developing DCVax® personalized immune therapies for cancer, announced the full exercise of the over-allotment option granted to the underwriters to purchase an additional 450,000 shares of common stock and warrants to purchase 225,000 shares, at a public offering price of $4.00 per share and $0.01 per warrant in connection with...
Read More
07
DEC
2012

Northwest Biotherapeutics Announces Public Offering of Common Stock and Warrants, and Listing on NASDAQ

Posted By :
Comments : Off
BETHESDA, MD, December 7, 2012 – Northwest Biotherapeutics, Inc. (NASDAQ: NWBO; NWBOW), a biotechnology company developing DCVax® personalized immune therapies for cancer, announced the pricing of an underwritten public offering of 3,000,000 shares of common stock, and warrants to purchase up to an aggregate 1,500,000 shares of common stock, at an offering price of $4.00 per share and $0.01 per warrant. The Warrants have a per share exercise...
Read More
06
NOV
2012

Northwest Bio Collaborating With Leading UK Cancer Institutions For DCVax® -Direct Trial

Posted By :
Comments : Off
Phase I/II Trial for Colon Cancer – Second Leading Cause of Cancer Deaths BETHESDA, MD, November 6 , 2012 — Northwest Biotherapeutics (OTCQB: NWBO) (NW Bio) a biotechnology company developing DCVax® personalized immune therapies for cancer, announced today that it has initiated a collaboration with Sarah Cannon Research UK and the Leaders in Oncology Care (LOC) on a Phase I/II trial with DCVax®-Direct for metastatic colon cancer. Sarah...
Read More
26
SEP
2012

Northwest Biotherapeutics Announces Reverse Split Of Common Stock

Posted By :
Comments : Off
First Step In Plan For Capital Raise And NASDAQ Listing BETHESDA, MD, Sept. 26, 2012 /PRNewswire/ — Northwest Biotherapeutics (NWBO:OTC QB) (NW Bio), a biotechnology company developing DCVax® personalized immune therapies for cancer, announced that on September 25, 2012 at 5:00 p.m. EDT (the”Effective Date”) it effected a one (1) for sixteen (16) reverse split of its issued and outstanding common stock (the “Reverse Split”) as a first...
Read More